Cancer cell proliferation requires a robust increase in cellular metabolism to support the massive anabolic requirements for the generation of two daughter cells. Cancer cells engage in multiple glucose- and mitochondrial-dependent anabolic pathways to generate the precursors required for lipid, nucleotide, and protein synthesis as well as to produce NADPH, which provides the reducing equivalents for biosynthesis. Oncogenic signaling and tumor-suppressor loss activate these anabolic pathways to support tumor growth. Indeed, as a consequence of mitochondrial metabolism, the reactive oxygen species (ROS) generated by the mitochondrial electron transport chain (ETC) are essential for cancer cell proliferation, tumorigenesis, and metastasis (1). When rapidly proliferating tumor cells outgrow their available blood supply, regions within a solid tumor become hypoxic (i.e., have low oxygen levels). Hypoxia also increases the production of mitochondrial ROS to activate the HIF family of transcription factors and induce the expression of HIF target genes, including those involved in metabolism and angiogenesis. Importantly, cancer cells need to maintain a steady-state level of ROS, a redox balance, which allows for cell proliferation and HIF activation without allowing ROS to accumulate to levels that would incur cell death or senescence. Thus, mitochondrial ROS levels are tightly regulated in cancer cells. Ye and colleagues demonstrate that serine catabolism through one-carbon metabolism maintains this mitochondrial redox balance during hypoxia (2).

During one-carbon metabolism, serine is converted to glycine in the cytosol and mitochondrial matrix by serine hydroxymethyl transferase 1 and 2 (SHMT1 and 2), respectively. This reaction involves the covalent linkage of tetrahydrofolate (THF), derived from folic acid, to a methylene group (CH2) to form 5,10-methenyl-tetrahydrofolate (5,10-CH2-THF). Cytosolic and mitochondrial methylenetetrahydrofolate dehydrogenase (MTHFD1 and 2, respectively) use 5,10-CH2-THF and NADPH as substrates to produce 5,10-methenyl-tetrahydrofolate (5,10-CH=THF) and NADPH (Figure 1). Subsequently, 5,10-CH=THF is converted into 10-formyl-THF, which is used for purine synthesis. Thus, serine catabolism through one-carbon metabolism supports cancer cell proliferation (3). Recently, several studies have highlighted the role of serine in tumorigenesis. For example, the initial cytosolic enzyme in the de novo serine synthesis pathway, phosphoglycerate dehydrogenase (PHGDH), is upregulated in breast cancer and melanoma (4, 5). Moreover, many tumor cells are highly dependent on the uptake of exogenous serine, suggesting that the de novo serine synthesis by itself is not sufficient to meet the requirements for cell proliferation (6).

Given that one-carbon THF units are required for nucleotide synthesis, cancer cells benefit from enhanced serine-dependent one-carbon metabolism. Notably, serine is primarily catalyzed through the mitochondrial one-carbon metabolism pathway. If carbon units of THF are needed solely for nucleotide synthesis in the cytosol, why do cells engage in the mitochondrial one-carbon metabolism pathway? A recent elegant study that uses a new method for tracing NADPH compartmentalization revealed that serine functions in the mitochondrial one-carbon metabolism pathway to produce NADPH (7). An independent study also demonstrated that serine and glycine catabolism in the mitochondria generates NADPH (8). However, whether this source of NADPH is important for cancer cell proliferation and tumor growth remained unknown.

In this issue of Cancer Discovery, Ye and colleagues (2) not only describe the importance of the mitochondrial one-carbon metabolism pathway but also provide mechanistic insight into the role of serine in NADPH production for mitochondrial redox homeostasis during hypoxia and tumor growth. NADPH plays a critical role in maintaining the cellular antioxidant capacity by regenerating the reduced pools of glutathione (GSH) and thioredoxin (TRX), ROS scavengers that remove excess hydrogen peroxide (H2O2). Ye and colleagues observed a drastic increase in the amount of mitochondrial ROS produced in SHMT2-knockdown cells under hypoxia compared with normoxia. Moreover, these cells had
lower NADPH/NADP⁺ and glutathione/glutathione disulfide (GSH/GSSG) ratios during hypoxia, resulting in increased cell death. Importantly, this effect was rescued when the cells were treated with the antioxidant N-acetyl-L-cysteine (NAC), implicating elevated ROS in the increased cell death of SHMT2-knockdown cells. Furthermore, cancer cells with decreased SHMT2 also display impaired tumor growth. Thus, mitochondrial serine catabolism is necessary for NADPH production, ROS detoxification, and cancer cell survival. Importantly, SHMT2 but not SHMT1 is overexpressed in a variety of human cancers, and breast cancer patients with low SHMT2 expression survive better compared to those with high SHMT2 expression. In addition, there is a positive correlation between mitochondrial SHMT2 (serine catabolism) and cytosolic PHGDH (serine biosynthesis) in various cancer cell types. This correlation is not observed between the two cytosolic proteins, PHGDH and SHMT1. This suggests that cancer cells coordinate the de novo synthesis of serine in the cytosol and the catabolism of serine in the mitochondrial matrix to produce NADPH for detoxification of ROS needed to sustain tumor growth (Figure 1).

In addition, Ye and colleagues observed that the expression of SHMT2 positively correlated with the expression of HIF-regulated enzymes under hypoxia and confirmed hypoxia-induced upregulation of SHMT2 in a HIF1-dependent manner in cancer cells (2). Interestingly, hypoxic induction of SHMT2 was observed only in cancer cells with MYC amplification. Because SHMT2 is a reported MYC target gene, Ye and colleagues further investigated whether MYC was also driving SHMT2 upregulation. Indeed, they confirmed that the induction of SHMT2 under hypoxia was dependent on MYC-driven transcriptional amplification, indicating that both HIF and MYC collaborate to induce SHMT2 expression (Figure 1). This finding was quite unexpected as previous results in clear cell renal cell carcinoma have demonstrated that HIF1α antagonizes c-MYC function (9). Further studies are necessary to elucidate the circumstances for which HIF1α and MYC cooperate or antagonize to regulate gene expression.

The degree of hypoxia positively correlates with metastasis; thus, it will be of interest to determine whether enzymes in the one-carbon metabolism pathway predict metastatic progression. It will also be important to assess whether targeting these metabolic enzymes diminishes both primary tumor growth and metastasis. Moreover, given that MYC expression is deregulated in numerous tumor types, the finding that SHMT2 induction occurs only in MYC-amplified cancer cells during hypoxia makes SHMT2 an attractive therapeutic target. Furthermore, p53-null tumors are highly sensitive to exogenous serine depletion (6), suggesting that mitochondrial one-carbon metabolism may prove to be an efficacious cancer therapy in MYC-overexpressing and p53-null tumors. Interestingly, anti-folate agents that disrupt one-carbon metabolism (folic acid is the precursor for the one-carbon metabolism) were shown to be ineffective in MYC-overexpressing tumors (6), suggesting that these agents do not target MYC-dependent pathways.
unit donor THF) have been used clinically for decades and thus there is precedence for targeting this pathway. A key concern with inhibiting mitochondrial one-carbon metabolism is whether cancer cells exhibit metabolic plasticity to compensate for the loss of NADPH production. It is important to note that within the mitochondrial matrix NADPH can also be generated by isocitrate dehydrogenase 2 (IDH2) and malic enzyme 3 (ME3). Another important consideration is whether normal cells require mitochondrial one-carbon metabolism for maintaining redox balance. Although Shmt2-knockout mice have yet to be generated, Mthfd2-knockout mice are embryonic lethal. Given the hypoxic microenvironment of a developing embryo, it is not surprising that mice lacking a key enzyme within the mitochondrial one-carbon metabolism pathway are embryonic lethal. However, normal adult tissues might not require these mitochondrial one-carbon metabolism enzymes, as mitochondrial oxidative stress is low and nutrients such as glucose and oxygen are not limiting. Indeed, MTHFD2 was absent in most adult tissues, in stark contrast with the developing embryo (10). Meta-analysis data showed that MTHFD2 is the most consistently overexpressed metabolic enzyme across multiple tumor types and is correlated with poor survival in breast cancer (10). Thus, targeting mitochondrial one-carbon metabolism for cancer treatment is a potential therapeutic approach. However, a major hurdle for inhibitors targeting this pathway is diffusibility through the lipid membranes, including the cell membrane, outer mitochondrial membranes, and inner mitochondrial membranes. To overcome this obstacle, a lipophilic cation can be attached to small molecules to increase their accumulation in the mitochondrial matrix 100- to 500-fold greater in concentration than outside the cell due to the large negative membrane potential generated by the ETC across the mitochondrial inner membrane. Thus, in summary, Ye and colleagues (2) have unveiled mitochondrial one-carbon metabolism as a promising pathway for targeted cancer therapy, especially in hypoxic tumors where, to date, the therapeutic options are limited.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Grant Support
N.S. Chandel is supported by the NIH (grant R01 CA12306708).
I. Martinez-Reyes is supported by the Ramon Areces Foundation of Spain.

Published online December 4, 2014.

REFERENCES
Mitochondrial One-Carbon Metabolism Maintains Redox Balance during Hypoxia

Inmaculada Martínez-Reyes and Navdeep S. Chandel

*Cancer Discovery* 2014;4:1371-1373.

**Updated version**
Access the most recent version of this article at:
http://cancerdiscovery.aacrjournals.org/content/4/12/1371

**Cited articles**
This article cites 10 articles, 1 of which you can access for free at:
http://cancerdiscovery.aacrjournals.org/content/4/12/1371.full#ref-list-1

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.